<SEC-DOCUMENT>0001193125-19-236598.txt : 20191108
<SEC-HEADER>0001193125-19-236598.hdr.sgml : 20191108
<ACCEPTANCE-DATETIME>20190903164302
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-19-236598
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190903

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vir Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001706431
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				812730369
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-906-4324

	MAIL ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g755217g28j02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laura A. Berezin</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 650 843 5128</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">lberezin@cooley.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">By EDGAR and courier</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 3, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irene Paik
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mary Beth Breslin </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ibolya Ignat </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Angela Connell </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Healthcare&nbsp;&amp; Insurance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Vir Biotechnology, Inc. </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment No.&nbsp;1 to Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT>
</B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Submitted August&nbsp;7, 2019 </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CIK No.&nbsp;0001706431 </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mses. Paik, Breslin, Ignat and Connell: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of Vir Biotechnology, Inc. (&#147;<B>Vir</B>&#148; or the &#147;<B><I>Company</I></B>&#148;) we submit this letter in response to
comments received from the staff (the &#147;<B><I>Staff</I></B>&#148;) of the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) by letter dated August&nbsp;23, 2019 (the &#147;<B><I>Comment Letter</I></B>&#148;) with
respect to the Company&#146;s Amendment No.&nbsp;1 to the Company&#146;s Confidential Draft Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> submitted to the Commission on August&nbsp;7, 2019 (&#147;<B><I>DRS Amendment
No.</I></B><B><I></I></B><B><I>&nbsp;1</I></B>&#148;). Concurrently with the submission of this response letter, the Company is filing the Company&#146;s Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (the
&#147;<B><I>Registration Statement</I></B>&#148;). In addition to addressing the comments raised by the Staff in the Comment Letter, the Company has included other revisions and updates to its disclosure in the Registration Statement. For the
Staff&#146;s reference, we have included two copies of the Registration Statement marked to show all changes from DRS Amendment No.&nbsp;1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the convenience of the Staff, the numbering of the paragraphs below corresponds to the numbering of the comment in the Comment Letter, the
text of which we have incorporated into this response letter for convenience in italicized type and which is followed by the Company&#146;s response. In the responses below, page number references are to the Registration Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Amendment No.&nbsp;1 to Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> submitted August&nbsp;7, 2019 </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Prospectus Summary </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Our Development Pipeline, page 2
</U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your revisions in response to our prior comment 8. Please also revise your description of the
initial data from the clinical study of <FONT STYLE="white-space:nowrap">VIR-2218</FONT> in the Summary to disclose the number of patients that have received <FONT STYLE="white-space:nowrap">VIR-2218</FONT> as a treatment. In addition, please revise
your description of the initial data throughout the prospectus to disclose not only the reduction in HBsAg, but the baseline levels of HBsAg in treated patients, since the FDA accepts levels of HBsAg less than 0.05 IU/ml as demonstrating a
functional cure.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on
pages&nbsp;2&#150;3, 98, 112 and 115 of the Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175
Hanover Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000 f: (650) 849-7400 cooley.com </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g755217g28j02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 3, 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Business </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Our Corporate History, page 96 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your response to our prior comment 6. Since you are not involved in the clinical development of
mAb114 and you determined not to pursue a sublicense opportunity to develop mAb114 in collaboration with the NIH, please remove from your corporate timelines on pages&nbsp;76 and 96 the start of Phase&nbsp;2/3 clinical trials for mAb114. We would
object to including a marker in the timeline for when mAb114 was identified with additional disclosure regarding your collaboration with the NIH.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on pages&nbsp;76 and 99 of the Registration
Statement to remove references to mAb114 from the corporate timelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please contact me at (650) <FONT STYLE="white-space:nowrap">843-5128,</FONT> Charles Kim at (858)
<FONT STYLE="white-space:nowrap">550-6049</FONT> or Kristin VanderPas at (415) <FONT STYLE="white-space:nowrap">693-2097</FONT> with any questions or further comments regarding our response to the Staff&#146;s comment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Laura A. Berezin </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laura A. Berezin </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Scangos, Ph.D., Vir Biotechnology, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Howard Horn, Chief Financial Officer, Vir Biotechnology, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Irene Pleasure, VP, Intellectual Property&nbsp;&amp; Associate General Counsel, Vir Biotechnology, Inc.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Charles S. Kim, Cooley LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kristin VanderPas, Cooley LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Brian J. Cuneo, Latham&nbsp;&amp; Watkins LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">B. Shayne Kennedy, Latham&nbsp;&amp; Watkins LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Drew Capurro, Latham&nbsp;&amp; Watkins LLP </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 3175
Hanover Street Palo Alto, CA 94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000 f: (650) 849-7400 cooley.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g755217g28j02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g755217g28j02.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M+<SA2J5/@BWZ(=!<P74?F6\T<T?3=&P8?F*$T]A3A*#M)68YIHD;:TB*WH6
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M'VLJ-+-J%.J^CO\ YHZ_X5Z&;?3I]9G7][='9$3UV \G\2/TK;#PLN8\;/\
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M,JXNISU'_DBEXH\'V'B>!3-F&[C&(YT'(]B.XI5*:F;X#,JN"E[NL7NCB/\
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M73DH@G0JQSRS8/KP,_6N>A!IN4CZ#.\;3E".'H-.*UTV\E_7D>CUU'S 4 %
A!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
